Waldenstrom's Macroglobulinemia

  • Lijo Simpson
  • Morie Gertz
Part of the Contemporary Hematology book series (CH)

Waldenstroms macroglobulinemia (WM) was first described by Jan Waldenstrom in 1944. He described two patients with oronasal bleeding, lymphadenopathy, normochromic anemia, increased erythrocyte sedimentation rate (ESR), thrombocytopenia, hypoalbuminemia, low serum fibrinogen, and increased number of lymphoid cells in bone marrow.1 Waldenstrom went on to point out: “The cellular basis of macroglobulinemia is the proliferation of one clone of cells that produces one definitive macroglobulin molecule. These cells may appear in different histological patterns. The most common is diffuse infiltration of the bone marrow but many patients also have enlargement of lymph glands (“lymphoma”). In some instances the spleen is also invaded and rare patients have a lymphoma picture in the lungs and even in the brain. The characteristic finding is that these cells contain immunoglobulin M (IgM) with the same light-chain type, either λ (kappa) or κ (lambda), as the increased IgM in the serum.”2



Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Overall Response Rate Malt Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Waldenstrom J. Incipient myelomatosis or “essential” hyperglobulinema with fibrinogenopenia. A new syndrome? Acta Med Scand. 1944;117:216–22.Google Scholar
  2. 2.
    Waldenström J. Macroglobulinemia. A review. Haematologica 1986;71:437–40.PubMedGoogle Scholar
  3. 3.
    Vijay A, Gertz MA. Waldenstrom Macroglobulinemia. Blood. 2007 Feb 15; [Epub ahead of print].Google Scholar
  4. 4.
    Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenstroms macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer. 1998;82(6):1078–81.PubMedGoogle Scholar
  5. 5.
    Linet MS, Humphrey RL, Mehl ES, Brown LM, Pottern LM, Bias WB, McCaffrey L Acase-control and family study ofWaldenstroms macroglobulinemia. Leukemia. 1993;7(9):1363–9.PubMedGoogle Scholar
  6. 6.
    Williamson LM, Greaves M, Waters JR, Harling CC. Waldenstroms macroglobuli-naemia: three cases in shoe repairers. BMJ. 1989;298:498–9.PubMedGoogle Scholar
  7. 7.
    Travis LB, Li CY, Zhang ZN, Li DG, Yin SN, Chow WH, et al. Hematopoietic malignancies and related disorders among benzene-exposed workers in China. Leuk Lymphoma. 1994;14:91–102.PubMedGoogle Scholar
  8. 8.
    Fine JM, Muller JY, Rochu D, Marneux M, Gorin NC, Fine A, Lambin P. Waldenstroms macroglobulinemia in monozygotic twins. Acta Med Scand. 1986;220(4):369–73.PubMedGoogle Scholar
  9. 9.
    Renier G, Ifrah N, Chevailler A, Saint-Andre JP, Boasson M, Hurez D. Four brothers with Waldenstrom's macroglobulinemia. Cancer. 1989;64(7):1554–9.PubMedGoogle Scholar
  10. 10.
    McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):146–52.PubMedGoogle Scholar
  11. 11.
    Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Ditzel Santos1 D Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson1 CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol. 2006;17(3):488–94.PubMedGoogle Scholar
  12. 12.
    Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/Waldenstroms macroglob ulinemia: an evolving concept. Adv Anat Pathol. 2005;12(5):246–55.PubMedGoogle Scholar
  13. 13.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMedGoogle Scholar
  14. 14.
    Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:132–4.Google Scholar
  15. 15.
    Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, Morgan GJ, Jack AS. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116(3):420–8.PubMedGoogle Scholar
  16. 16.
    San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:187–95.PubMedGoogle Scholar
  17. 17.
    KonoplevS,MedeirosLJ,Bueso-RamosCE,JorgensenJL,LinP. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005;124(3):414–20.PubMedGoogle Scholar
  18. 18.
    Owen RG, Hillmen P, Rawstron AC, et al. CD52 expression in Waldenström's mac roglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma. 2005;5:278–81.PubMedGoogle Scholar
  19. 19.
    Offit K, Parsa NZ, Filippa D, et al. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood. 1992;80:2594–9.PubMedGoogle Scholar
  20. 20.
    Iida S, Rao PH, Ueda R, et al. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma. 1999;34:25–33.PubMedGoogle Scholar
  21. 21.
    Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos CE. Cytogenetic findings in lymphoplasmacytic lym phoma/Waldenstroms macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116(4):543–9.PubMedGoogle Scholar
  22. 22.
    Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100(8):2996–3001.PubMedGoogle Scholar
  23. 23.
    Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K. Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogen-esis of 20q11 anomaly. Cancer Genet Cytogenet. 2006;169:69–72.PubMedGoogle Scholar
  24. 24.
    Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136(1):80–6.PubMedGoogle Scholar
  25. 25.
    Chang WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108(8):2755–63. Epub 2006 Jun 27.Google Scholar
  26. 26.
    Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin 6 in human multiple myeloma. Blood. 1995;85:863–72.PubMedGoogle Scholar
  27. 27.
    Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobuline mia. Eur J Haematol. 2001;66:1–6.PubMedGoogle Scholar
  28. 28.
    Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001;2:1103–8.PubMedGoogle Scholar
  29. 29.
    Hunter Z, Leleu X, Hatjiharissi E, Santos D, Xu L, Ho A, et al. IgA and IgG hypogam-maglobulinemia are associated with mutations in the APRIL/BLYS receptor TACI in Waldenström's. Blood. (ASH Annual Meeting Abstracts) 2006;108:Abstract 228.Google Scholar
  30. 30.
    Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, et al. B-lym phocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood. 2006;107:2882–8. Epub 2005 Nov 22.PubMedGoogle Scholar
  31. 31.
    Adamia S, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM. Abnormal expression of hyaluronan synthases in patients with Waldenström's macroglob ulinemia. Semin Oncol. 2003;30:165–8.PubMedGoogle Scholar
  32. 32.
    Adamia S, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, et al Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenström's macroglobulinemia. Clin Lymphoma. 2005;5:253–6.PubMedGoogle Scholar
  33. 33.
    Kriangkum J, Taylor BJ, Reiman T, et al. Origins of Waldenstroms macroglob ulinemia: does it arise from an unusual B-cell precursor ? Clin Lymphoma. 2005;5:217–9.PubMedGoogle Scholar
  34. 34.
    Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc. 1987;62(8):719–31.PubMedGoogle Scholar
  35. 35.
    Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006;145:435–47.PubMedGoogle Scholar
  36. 36.
    Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol. 2004;11(6):411–8.PubMedGoogle Scholar
  37. 37.
    Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman S R, Roy V Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82(3):323–41.PubMedGoogle Scholar
  38. 38.
    Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori infection and gastric lym phoma. N Engl J Med. 1994;330(18):1267–71.PubMedGoogle Scholar
  39. 39.
    Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B, Gutierrez NC, Orfao A, San Miguel JF. Immunophenotypic and cytogenetic comparison of Waldenstroms macroglobulinemia with splenic marginal zone lym phoma. Clin Lymphoma. 2005;5(4):241–5.PubMedGoogle Scholar
  40. 40.
    Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstroms macr oglob ulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214–26.PubMedGoogle Scholar
  41. 41.
    Dimopoulos MA, Alexanian R. Waldenstroms macroglobulinemia. Blood. 83:1452–9.Google Scholar
  42. 42.
    Fudenberg HH, Virella G. Multiple myeloma and Waldenstroms macroglobuline mia: unusual presentations. Semin Hematol. 1980;17(1):63–79. ReviewPubMedGoogle Scholar
  43. 43.
    Lin P, Buesco-Ramos C, Wilson CS, et al. Waldenstrom macroglobulinemia involving extramedullary sites. Am J Surg Pathol. 2003;27:1104–13.PubMedGoogle Scholar
  44. 44.
    Fadil A, Taylor DE. The lung and Waldenstroms macroglobulinemia. South Med J. 1998;91:681–5.PubMedGoogle Scholar
  45. 45.
    Oveliama J, Friedman AH. Ocular manifestations of multiple myeloma, Waldenstroms macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol. 1981;26:157–69.Google Scholar
  46. 46.
    Civit T, Coulbois S, Baylac F, et al. Waldenstroms macroglobulinemia and cerebral lymphoplasmacytic proliferation: Bing and Neel syndrome—Apropos of a new case. Neurochirurgie. 1997;43:245–9.PubMedGoogle Scholar
  47. 47.
    Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenström? Bull Soc Fr Derm Syph. 1974;81:363–7.Google Scholar
  48. 48.
    Rosenthal JA, Curran WJ Jr, Schuster SJ. Waldenström's macroglobulinemia resulting from localized gastric lymphoplasmacytoid lymphoma. Am J Hematol. 1998;58:244–5.PubMedGoogle Scholar
  49. 49.
    Dimopoulos MA, Galani E, Matsouka C. Waldenstroms macroglobulinemia., Hematol Oncol Clin North Am. 1999;13(6):1351–66.PubMedGoogle Scholar
  50. 50.
    Dimopoulos MA, Kyle RA, AnagnostopoulosA, and Treon SP. Diagnosis and Management of Waldenstrom's Macroglobulinemia. J Clin Oncol. 2005;23(7):1564–77.PubMedGoogle Scholar
  51. 51.
    Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med. 1995;10:128–41.PubMedGoogle Scholar
  52. 52.
    Farhangi M, Merlini G. The clinical implications of monoclonal immunoglobulins. Semin Oncol. 1986;13:366–79.PubMedGoogle Scholar
  53. 53.
    Libow LF, Mawhinney JP, Bessinger GT. Cutaneous Waldenstrom's macroglob ulinemia: report of a case and overview of the spectrum of cutaneous disease. Am Acad Dermatol. 2001;45(6 Suppl):S202–6.Google Scholar
  54. 54.
    Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM. Waldenstrom's mac roglobulinemia associated with AA amyloidosis. Int J Hematol. 2001;74(1):76–8.PubMedGoogle Scholar
  55. 55.
    Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglob ulinemia. J Clin Oncol. 1993;11:914–20.PubMedGoogle Scholar
  56. 56.
    Baldini L, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L,. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenström's macroglobuline mia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45:25–31.PubMedGoogle Scholar
  57. 57.
    Kwan JY. Paraproteinemic neuropathy. Neurol Clin. 2007;25(1):47–69.PubMedGoogle Scholar
  58. 58.
    Dalakas MC, Flaum MA, Rick M, : Treatment of polyneuropathy in Waldenstrom's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology. 1983;33:1406–10.PubMedGoogle Scholar
  59. 59.
    Bryce AH, Kyle RA, Dispenzieri A, Gertz MA. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol. 2006;81(7):511–8.PubMedGoogle Scholar
  60. 60.
    Lindstrom FD, Hed J, Enestrom S. Renal pathology of Waldenstrom's macroglob ulinemia with monoclonal antiglomerular antibodies and nephritic syndrome. Clin Exp Immunol. 1980;41:196–204.PubMedGoogle Scholar
  61. 61.
    Sen HN, Chan CC, Caruso RC, et al. Waldenstrom's macroglobulinemia-associ ated retinopathy. Ophthalmology. 2004;111:535–9.PubMedGoogle Scholar
  62. 62.
    Bradley JR, Thiru S, Bajallan N, Evans DB. Renal transplantation in Waldenstrom's macroglobulinaemia. Nephrol Dial Transplant. 1988;2:214–6.Google Scholar
  63. 63.
    Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):206–10.PubMedGoogle Scholar
  64. 64.
    Gobbi PJ, Bettini R, Montecucco C, et al. Study of Prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939–45.PubMedGoogle Scholar
  65. 65.
    Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000 ; 96:852–8.PubMedGoogle Scholar
  66. 66.
    Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom mac roglobulinaemia. Br J Haematol. 2006;133(2):158–64.PubMedGoogle Scholar
  67. 67.
    Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel recommendation from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:127–31.PubMedGoogle Scholar
  68. 68.
    Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenström's macroglobulinemia. J Clin Oncol. 2005;23(7):1564–77.PubMedGoogle Scholar
  69. 69.
    Kaplan AA. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher. 2001;5:171–5.PubMedGoogle Scholar
  70. 70.
    Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Semin Thromb Hemost. 2003;29:535–42.PubMedGoogle Scholar
  71. 71.
    Humphrey JS, Conley CL. Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature. Am J Hematol. 1995;48(4):262–6.PubMedGoogle Scholar
  72. 72.
    Takemori N, Hirai K, Onodera R, Kimura S, Katagiri M. Durable remission after splenectomy for Waldenstrom's macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymphoma. 1997;26(3–4):387–93.PubMedGoogle Scholar
  73. 73.
    Kyle, RA, Greipp, PR, Gertz, MA, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737.PubMedGoogle Scholar
  74. 74.
    Annibali O, Petrucci MT, Martini V, Tirindelli MC, Levi A, Fossati C, Del Bianco P, Mandelli F, Foa R, Avvisati G. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and pred nisone: results and cost analysis. Cancer. 2005;103(3):582–7.PubMedGoogle Scholar
  75. 75.
    Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98(1):41–8.PubMedGoogle Scholar
  76. 76.
    Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol. 2003;30(2):220–5.PubMedGoogle Scholar
  77. 77.
    Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98(9):2640–4.PubMedGoogle Scholar
  78. 78.
    Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2005;6(2):136–9.PubMedGoogle Scholar
  79. 79.
    Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's (12):2694–8.Google Scholar
  80. 80.
    Fridrik MA, Jager G, Baldinger C, et al. First-line treatment of Waldenstrom's disease with cladribine. Ann Hematol. 1997;74:7–10.PubMedGoogle Scholar
  81. 81.
    Hellmann A, Lewandowski K, Zauche JM. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol. 1999;63:35–41.PubMedGoogle Scholar
  82. 82.
    Delannoy A, Van de Neste E, Michaux JL, et al. Cladribine for Waldenstrom's macroglobulinemia. Br J Haematol. 1999;104:933–4.PubMedGoogle Scholar
  83. 83.
    Hampshire A, Saven A: update of bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood. 2003;102:402a, (abstr).Google Scholar
  84. 84.
    Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclo-phosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's Macroglobulinemia /lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma. 2005;6(2):131–5.PubMedGoogle Scholar
  85. 85.
    Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant. 2006;12(8):845–54.PubMedGoogle Scholar
  86. 86.
    Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous hae mopoietic stem cell support for Waldenstrom's macroglobulinemia. Br J Haematol. 1999;105:993–6.PubMedGoogle Scholar
  87. 87.
    Anagnostopoulos A, Dimopoulos MA, Aleman A, et al. High-dose chemotherapy followed by stem-cell transplantation in patients with resistant Waldenstrom's mac roglobulinemia. Bone Marrow Transplant. 2001;27:1027–9.PubMedGoogle Scholar
  88. 88.
    Toumilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenstrom's mac roglobulinemia: the French experience. Semin Oncol. 2003;30:291–6.Google Scholar
  89. 89.
    Dreger P, Stilgenbauers S, Seyfarth B, et al. Autologous and allogeneic stem cell transplantation for treatment of Waldenstrom's macroglobulinemia, 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 70.Google Scholar
  90. 90.
    Fassas A, Dhodapkar M, Mc Coy J, et al. Management of Waldenstrom's mac roglobulinemia in the pre-rituximab era: update on US Intergroup Trial 59003 and the Arkansas autotransplant experience, 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 59.Google Scholar
  91. 91.
    Maloney DG, Sandmaier BM, Maris M, et al. Allogeneic hematopoietic cell transplantation for refractory Waldenstrom's macroglobulinemia: replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood. 2003;102:472b, (abstr).Google Scholar
  92. 92.
    Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(3):474–81.PubMedGoogle Scholar
  93. 93.
    Dimopoulos MA, Zervas C Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenstroms macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327–33.PubMedGoogle Scholar
  94. 94.
    Weng WK, Levy R. Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–47.PubMedGoogle Scholar
  95. 95.
    Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(3):474–81.PubMedGoogle Scholar
  96. 96.
    Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's mac-roglobulinemia with rituximab. J Clin Oncol. 2002;20:2327–33.PubMedGoogle Scholar
  97. 97.
    Dimopoulos MA, Zervas K, Zomas A, et al. Treatment of Waldenstrom's mac roglobulinemia with rituximab: prognostic factors for responses and progression. Leuk Lymphoma. 2004;45:2057–61.PubMedGoogle Scholar
  98. 98.
    Treon P, Emmanoullides CA, Kimby E, et al: Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol. 2005;16:132–8.PubMedGoogle Scholar
  99. 99.
    Ghobrial IM, Fonseca R, Greipp PR, et al. The initial “flare” of IgM level after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia. An Eastern Cooperative Oncology Group Study. Blood. 2003;102:448a, (abstr).Google Scholar
  100. 100.
    Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15:1481–3.PubMedGoogle Scholar
  101. 101.
    Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77(4):329–30.PubMedGoogle Scholar
  102. 102.
    Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5(4):273–7.PubMedGoogle Scholar
  103. 103.
    Treon SP, Branagan A, Wasi P, et al. Combination therapy with rituximab and fludarabine in Waldenstrom's macroglobulinemia. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October 2004, p 27.Google Scholar
  104. 104.
    Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's mac roglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma. 2005;5(4):278–81.PubMedGoogle Scholar
  105. 105.
    Owen RG, Rawstron AC, Osterborg A, et al. Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood. 2003;102:644a, (abstr).Google Scholar
  106. 106.
    Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's mac roglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596–601.PubMedGoogle Scholar
  107. 107.
    Coleman M, Leonard J, Lyona L, et al. Treatment of Waldenstrom's macroglob ulinemia with clarithromycin, low-dose thalidomide and dexamethasone. Semin Oncol. 2003;30:270–4.PubMedGoogle Scholar
  108. 108.
    Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's mac roglobulinemia with single-agent thalidomide or with the combination of clari thromycin, thalidomide and dexamethasone. Semin Oncol. 2003;30:265–9.PubMedGoogle Scholar
  109. 109.
    Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570–5. Epub 2007 Mar 12.PubMedGoogle Scholar
  110. 110.
    Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobuline mia with bortezomib. Haematologica. 2005;90(12):1655–8.PubMedGoogle Scholar
  111. 111.
    Frankel S. Oblimersen sodium (G 3139 Bcl–2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:300–4.PubMedGoogle Scholar
  112. 112.
    Treon SP, Tourmihac O, Branagan AR, et al. Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2004;5:205–7.PubMedGoogle Scholar
  113. 113.
    Patterson CJ, Soumerai J, Hunter Z, Leleu X, Ghobrial I, Treon SP. Sildenafil citrate suppresses disease progression in patients with Waldenström's macroglob ulinemia [abstract]. J Clin Oncol. 2006;24(18 Suppl):435S.Google Scholar
  114. 114.
    Porrata LF, Markovic SN. Androgenic therapy for Waldenstrom's macroglob ulinemia. Am J Hematol. 2006;81(11):892–3.PubMedGoogle Scholar
  115. 115.
    Tsai DE, Maillard I, Downs LH, Alavi A, Nasta SD, Glatstein E, Schuster SJ. Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2004;45(3):591–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Lijo Simpson
    • 1
  • Morie Gertz
    • 1
  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations